S Ali1, M J Davies2,3, E M Brady3, L J Gray4, K Khunti2,3, S A Beshyah5, W Hanif6. 1. Department of Diabetes & Endocrinology, Imperial College Healthcare NHS Trust, London, UK. 2. Diabetes Research Centre, University of Leicester, Leicester. 3. Leicester Diabetes Centre, University Hospitals of Leicester, Leicester. 4. Department of Health Sciences, University of Leicester, Leicester, UK. 5. Center for Diabetes and Endocrinology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates. 6. Department of Diabetes & Endocrinology, University Hospital Birmingham, NHS Trust, Birmingham, UK. wasim.hanif@uhb.nhs.uk.
Abstract
BACKGROUND: Globally there are approximately 90 million Muslims with diabetes of which approximately 400 000 reside within the UK. The holy month of Ramadan is a fundamental practice of this religion of which fasting from sun-rise to sun-set is an integral part. This poses many potential risks for those with diabetes who wish to observe Ramadan. METHODS: The evidence base for best clinical management of Type 1 and Type 2 diabetes during Ramadan was reviewed. We reviewed current and previous recommendations for safe fasting during Ramadan. RESULTS: The risks associated with fasting in those with diabetes and preparing your patient for Ramadan are discussed. We have reviewed the evidence around diet-controlled diabetes and therapies including; metformin, acarbose, metglitinides, sulfonylureas, thiazolidinidiones, dipeptidyl peptidase-4 inhibitor (DPP-4), sodium glucose co-transporter -2 (SGLT-2) inhibitors, glucagon-like peptide -1 (GLP-1) receptor agonists and insulin. CONCLUSION: Up to date guidelines for the management of treatment regimes are set-out for those with Type 1 and Type 2 diabetes who wish to fast during Ramadan.
BACKGROUND: Globally there are approximately 90 million Muslims with diabetes of which approximately 400 000 reside within the UK. The holy month of Ramadan is a fundamental practice of this religion of which fasting from sun-rise to sun-set is an integral part. This poses many potential risks for those with diabetes who wish to observe Ramadan. METHODS: The evidence base for best clinical management of Type 1 and Type 2 diabetes during Ramadan was reviewed. We reviewed current and previous recommendations for safe fasting during Ramadan. RESULTS: The risks associated with fasting in those with diabetes and preparing your patient for Ramadan are discussed. We have reviewed the evidence around diet-controlled diabetes and therapies including; metformin, acarbose, metglitinides, sulfonylureas, thiazolidinidiones, dipeptidyl peptidase-4 inhibitor (DPP-4), sodium glucose co-transporter -2 (SGLT-2) inhibitors, glucagon-like peptide -1 (GLP-1) receptor agonists and insulin. CONCLUSION: Up to date guidelines for the management of treatment regimes are set-out for those with Type 1 and Type 2 diabetes who wish to fast during Ramadan.
Authors: Syed H Ahmed; Tahseen A Chowdhury; Sufyan Hussain; Ateeq Syed; Ali Karamat; Ahmed Helmy; Salman Waqar; Samina Ali; Ammarah Dabhad; Susan T Seal; Anna Hodgkinson; Shazli Azmi; Nazim Ghouri Journal: Diabetes Ther Date: 2020-09-09 Impact factor: 2.945
Authors: Mahmoud Ibrahim; Melanie J Davies; Ehtasham Ahmad; Firas A Annabi; Robert H Eckel; Ebtesam M Ba-Essa; Nuha Ali El Sayed; Amy Hess Fischl; Pamela Houeiss; Hinde Iraqi; Ines Khochtali; Kamlesh Khunti; Shabeen Naz Masood; Safia Mimouni-Zerguini; Samad Shera; Jaakko Tuomilehto; Guillermo E Umpierrez Journal: BMJ Open Diabetes Res Care Date: 2020-05
Authors: Jun Yang Lee; Chee Piau Wong; Christina San San Tan; Nazrila Hairizan Nasir; Shaun Wen Huey Lee Journal: BMJ Open Diabetes Res Care Date: 2017-05-08
Authors: Nazim Ghouri; Sufyan Hussain; Ruzwan Mohammed; Salem Arifi Beshyah; Tahseen A Chowdhury; Naveed Sattar; Aziz Sheikh Journal: BMJ Open Diabetes Res Care Date: 2018-06-04